144 related articles for article (PubMed ID: 22802566)
1. Foot pain: uncommon presentation of lung cancer.
Lamarca A; Hindi N; Belda-Iniesta C; de Castro J
BMJ Case Rep; 2012 Jul; 2012():. PubMed ID: 22802566
[TBL] [Abstract][Full Text] [Related]
2. Development and cross-validation of prognostic models to assess the treatment effect of cisplatin/pemetrexed chemotherapy in lung adenocarcinoma patients.
Mou W; Liu Z; Luo Y; Zou M; Ren C; Zhang C; Wen X; Wang Y; Tian Y
Med Oncol; 2014 Sep; 31(9):59. PubMed ID: 25119500
[TBL] [Abstract][Full Text] [Related]
3. [Long-term survival of patient with brain metastases from lung cancer treated by pemetrexed monotherapy].
Ito S; Ogawa Y; Harada H; Yamaguchi T; Munakata K
Gan To Kagaku Ryoho; 2012 May; 39(5):793-6. PubMed ID: 22584333
[TBL] [Abstract][Full Text] [Related]
4. Major and prolonged response to pemetrexed in two cases of lung adenocarcinoma with bronchioloalveolar carcinoma features.
Duruisseaux M; Cadranel J; Biron E; Pérol M; Guérin JC; Arpin D
Lung Cancer; 2009 Sep; 65(3):385-7. PubMed ID: 19346028
[TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blinded, multicenter, phase II study of pemetrexed, carboplatin, and bevacizumab with enzastaurin or placebo in chemonaïve patients with stage IIIB/IV non-small cell lung cancer: Hoosier Oncology Group LUN06-116.
Casey EM; Harb W; Bradford D; Bufill J; Nattam S; Patel J; Fisher W; Latz JE; Li X; Wu J; Hanna N
J Thorac Oncol; 2010 Nov; 5(11):1815-20. PubMed ID: 20881647
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma.
Huang XE; Tian GY; Cao J; Xu X; Lu YY; Wu XY; Liu J; Shi L; Xiang J
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6663-7. PubMed ID: 24377585
[TBL] [Abstract][Full Text] [Related]
7. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating lung cancer cells with strong thymidylate synthase reactivity in the peripheral blood of a patient with pulmonary adenocarcinoma treated with pemetrexed.
Christoph DC; Hoffmann AC; Gauler TC; Asuncion BR; Loewendick H; Peglow A; Hassan B; Tran C; Wynes MW; Schuler M; Eberhard WE; Hirsch FR
J Thorac Oncol; 2012 Apr; 7(4):766-7. PubMed ID: 22425929
[No Abstract] [Full Text] [Related]
9. More than 54 months survival of a patient with lung adenocarcinoma after maintenance therapy with pemetrexed.
Samelis G; Ekmektzoglou K; Giannakaki S; Tsiakou A
J BUON; 2010; 15(4):797. PubMed ID: 21229649
[No Abstract] [Full Text] [Related]
10. [A case of adenocarcinoma of the lung with malignant pleural effusion in elderly patient treated effectively by pemetrexed and carboplatin].
Tada A; Sakaguchi K; Kobayashi M; Kagoshima T; Yamazaki Y; Kamisawa O
Gan To Kagaku Ryoho; 2012 Mar; 39(3):425-7. PubMed ID: 22421772
[TBL] [Abstract][Full Text] [Related]
11. Sequential treatment of advanced-stage lung adenocarcinoma harboring wild-type EGFR gene: second-line pemetrexed followed by third-line erlotinib versus the reverse sequence.
Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
Anticancer Res; 2013 Aug; 33(8):3397-402. PubMed ID: 23898110
[TBL] [Abstract][Full Text] [Related]
12. [Role of pemetrexed in the treatment of advanced non-small-cell lung cancer: news from ASCO, 2008].
de Marinis F; Ricciardi S
Tumori; 2008; 94(5):suppl 3-13. PubMed ID: 19112963
[No Abstract] [Full Text] [Related]
13. Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.
Izzedine H; Escudier B; Rouvier P; Gueutin V; Varga A; Bahleda R; Soria JC
Ann Oncol; 2013 Sep; 24(9):2421-5. PubMed ID: 23798615
[TBL] [Abstract][Full Text] [Related]
14. Adenocarcinoma of the lung with metatarsal metastasis.
Kemnitz MJ; Erdmann BB; Julsrud ME; Jacobs PM; Ringstrom JB
J Foot Ankle Surg; 1996; 35(3):210-2. PubMed ID: 8807478
[TBL] [Abstract][Full Text] [Related]
15. Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases: A case report and literature review.
He G; Xiao X; Zou M; Zhang C; Xia S
Medicine (Baltimore); 2016 Aug; 95(32):e4401. PubMed ID: 27512852
[TBL] [Abstract][Full Text] [Related]
16. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
Omlin A; D'Addario G; Gillessen S; Cerny T; von Hessling A; Früh M
Lung Cancer; 2009 Sep; 65(3):383-4. PubMed ID: 19375814
[TBL] [Abstract][Full Text] [Related]
17. Pemetrexed-induced anaphylaxis.
Shah BK; Hewett Y
Acta Oncol; 2013 May; 52(4):881. PubMed ID: 23472834
[No Abstract] [Full Text] [Related]
18. A case of bone, lung, pleural and liver metastases from renal cell carcinoma which responded remarkably well to zoledronic acid monotherapy.
Miwa S; Mizokami A; Konaka H; Izumi K; Nohara T; Namiki M
Jpn J Clin Oncol; 2009 Nov; 39(11):745-50. PubMed ID: 19808839
[TBL] [Abstract][Full Text] [Related]
19. Clinical response to crizotinib retreatment after acquisition of drug resistance.
Matsuoka H; Kurata T; Okamoto I; Kaneda H; Tanaka K; Nakagawa K
J Clin Oncol; 2013 Jul; 31(19):e322-3. PubMed ID: 23715571
[No Abstract] [Full Text] [Related]
20. Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.
Tartarone A
Future Oncol; 2010 Dec; 6(12):1937-40. PubMed ID: 21142866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]